ICPT — Intercept Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $793.52m
- $713.07m
- $285.71m
U.S. STOCKS ON THE MOVE-Wynn Resorts, WeWork, Holley
Intercept Pharma down as FDA staff raises concerns over liver disease treatment
US FDA staff flag 'serious' safety risks for Intercept's NASH treatment (updated)
Intercept Pharma down as FDA staff raise concerns for liver disease treatment
US FDA staff flag liver damage concerns about Intercept's NASH treatment
Intercept Pharma rises on FDA's 'orphan drug' tag for liver disease therapy
Brief: Intercept Pharmaceuticals Receives FDA Orphan Drug Designation For The Fixed-Dose Combination Of Oca And Bezafibrate For The Treatment Of Primary Biliary Cholangitis
Intercept Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Intercept Pharmaceuticals posts Q1 sales USD 68 million
Brief: Intercept Expects To Complete Planned Interim Analyses From 2 Ongoing Phase 2 Studies Of OCA-bezafibrate In 2023
Brief: Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results And Provides Update On Commercial Launch Strategy For Nash
Intercept Pharmaceuticals Inc expected to post a loss of 65 cents a share - Earnings Preview
Brief: Intercept To Announce Q1 Results And Provide Update On Commercial Launch Strategy For Nash On April 27, 2023
U.S. RESEARCH ROUNDUP- Bath & Body Works, Constellation Brands, Travelers Companies
Brief: Intercept Pharmaceuticals - On March 24, Co Entered Into Sales Agreement With Cowen And Company, LLC With Respect To At Market Offering Program
Brief: Intercept Pharmaceuticals Inc - May Offer And Sell Shares Of Common Stock Of Up To $100 Million
Brief: Intercept Pharmaceuticals Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: Intercept Announces FDA Advisory Committee Meeting Date On Obeticholic Acid
U.S. RESEARCH ROUNDUP-DR Horton, KB Home, Vir Biotechnology